Activist 3i, LP Sells 2.8M Shares, Converts Preferred, and Injects $1.5M in Valion Bio
VBIO is trading near its 52-week low of $0.113 (15% above the low) on elevated volume (1.9× avg).
Summary
Activist investor 3i, LP sold 2.77 million shares, converted 3.1 million preferred shares, and invested $1.5 million in Valion Bio, maintaining its 9.9% beneficial ownership stake.
Key Events · Ownership and Investor Activity · VBIO
-
3i, LP Sells 2.77M Shares
3i, LP sold 927,850 shares on Aug 17 at $0.1798, 847,064 shares on Aug 18 at $0.1622, and 995,678 shares on Aug 19 at $0.1269, totaling 2,770,592 shares for approximately $430,000.
-
Preferred Stock Conversions
3i, LP converted 3,116,164 shares of Series C Preferred Stock on Aug 17 at $0.39 per share, adding to its common stock holdings.
-
New $1.5M Investment
3i, LP purchased 1,500 shares of Series B Preferred Stock at $1,000 per share and warrants to buy 1,153,847 common shares at $0.23708 per share for $1.5 million.
-
Beneficial Ownership at 9.9%
After these transactions, 3i, LP beneficially owns 2,050,200 shares, representing 9.9% of the 18,892,969 outstanding shares, constrained by a 9.99% blocker.
Analysis · VBIO · Life Sciences
3i, LP continues to reshape its stake in Valion Bio. The fund sold 2.77 million shares over three days at prices between $0.1269 and $0.1798, while simultaneously converting 3.1 million preferred shares at $0.39 per share and investing an additional $1.5 million through a new Letter Agreement. This mixed activity—selling common stock while converting preferred and providing fresh capital—reflects the activist's ongoing effort to gain control and stabilize the company's finances. The sales reduce 3i's direct common stock holdings, but the conversions and new investment keep its beneficial ownership near the 9.9% blocker limit. The new warrants, exercisable at $0.23708, are above the current stock price of $0.1299, indicating 3i's longer-term confidence in a recovery. This filing adds material new details to the activist campaign that began on August 3, 2026.
At the time of this filing, VBIO was trading at $0.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3M. The 52-week trading range was $0.11 to $3.66. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.